Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jul 2;12(1):377.
doi: 10.1186/s13287-021-02456-w.

Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis

Jingfei Fu  1 , Yanxue Wang  1 , Yiyang Jiang  1 , Juan Du  1 , Junji Xu  2 , Yi Liu  3
Affiliations
Meta-Analysis

Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis

Jingfei Fu et al. Stem Cell Res Ther. .

Abstract

Objectives: Over the past decades, many studies focused on mesenchymal stem cells (MSCs) therapy for bone regeneration. Due to the efficiency of topical application has been widely dicussed and systemic application was also a feasible way for new bone formation, the aim of this study was to systematically review systemic therapy of MSCs for bone regeneration in pre-clinical studies.

Methods: The article search was conducted in PubMed and Embase databases. Original research articles that assessed potential effect of systemic application of MSCs for bone regeneration in vivo were selected and evaluated in this review, according to eligibility criteria. The efficacy of MSC systemic treatment was analyzed by random effects meta-analysis, and the outcomes were expressed in standard mean difference (SMD) and its 95% confidence interval. Subgroup analyses were conducted on animal species and gender, MSCs types, frequency and time of injection, and bone diseases.

Results: Twenty-three articles were selected in this review, of which 21 were included in meta-analysis. The results showed that systemic therapy increased bone mineral density (SMD 3.02 [1.84, 4.20]), bone volume to tissue volume ratio (2.10 [1.16, 3.03]), and the percentage of new bone area (7.03 [2.10, 11.96]). Bone loss caused by systemic disease tended to produce a better response to systemic treatment (p=0.05 in BMD, p=0.03 in BV/TV).

Conclusion: This study concluded that systemic therapy of MSCs promotes bone regeneration in preclinical experiments. These results provided important information for the systemic application of MSCs as a potential application of bone formation in further animal experiments.

Keywords: Bone regeneration; Mesenchymal stem cells; Meta-analysis; Systemic treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart for study screening and selection
Fig. 2
Fig. 2
Risk of bias
Fig. 3
Fig. 3
The forest plot: the effects of MSCs therapy on BMD, compared with controls. 95% CI, 95% confidence interval
Fig. 4
Fig. 4
The forest plot: the effects of MSCs therapy on BV/TV, compared with controls. 95% CI, 95% confidence interval
Fig. 5
Fig. 5
The forest plot: the effects of MSCs therapy on the percentage of new bone area, compared with controls. 95% CI, 95% confidence interval
See this image and copyright information in PMC

References

    1. Oryan A, Alidadi S. Reconstruction of radial bone defect in rat by calcium silicate biomaterials. Life Sci. 2018;201:45–53. doi: 10.1016/j.lfs.2018.03.048. - DOI - PubMed
    1. Wang M, Park S, Nam Y, Nielsen J, Low SA, Srinivasarao M, Low PS. Bone-fracture-targeted dasatinib-oligoaspartic acid conjugate potently accelerates fracture repair. Bioconjug Chem. 2018;29(11):3800–3809. doi: 10.1021/acs.bioconjchem.8b00660. - DOI - PubMed
    1. Qaseem A, Forciea MA, McLean RM, Denberg TD. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–839. doi: 10.7326/M15-1361. - DOI - PubMed
    1. Kishimoto H, Noguchi K, Takaoka K. Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ) Jpn Dent Sci Rev. 2019;55(1):95–102. doi: 10.1016/j.jdsr.2018.09.002. - DOI - PMC - PubMed
    1. Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature. 1965;206(983):489–490. doi: 10.1038/206489a0. - DOI - PubMed

Publication types

LinkOut - more resources